2020’s health-sector IPO action is blasting off with the pricing of a China-based biggie and a bunch of new filings.

The US health-sector IPO action continues to scramble for public funding leadership. And it’s beginning with a Chinese company that raked in over $100 million. Let’s check out the action… Read more »

Drug regulators in China, US and Europe out of the gates in 2020 with a whole month’s worth of action.

Slowly at first, then accelerating recently in its domestic and global footprint in drug research and regulation, China and its National Medical Products Administration (NMPA) has been on a tear…. Read more »

Health-sector IPO action picks up where 2019 left off with new SEC filings signaling high hopes for cash still parked on the sidelines.

Despite clashes over trade sanctions pending resolution with China and threats of war with Iran escalating to nerve-wracking heights, confidence in the US market for health-sector initial public offerings apparently… Read more »

China’s BeiGene gets nod from FDA for lymphoma med; significance extends further than just a win for one Chinese biotech.

The News: The US Food and Drug Administration has given the green light to market a blood cancer drug from Beijing-based BeiGene Ltd., paving the way for American patients to access a Chinese… Read more »

FDA panel unanimously backs use of Amarin’s fish-oil heart drug; action could produce gigantic profit haul.

The News: Government health experts recently recommended broader use of a prescription-strength fish oil drug to help many more patients at risk for heart attack, stroke and related health problems…. Read more »

In a seeming role-reversal, FDA steps up action over Thanksgiving week while EMA goes on holiday.

Although usually thought of as a well-deserved respite from governmental rulings, the US Food and Drug Administration seized on Thanksgiving week as a demonstration of its zeal to pump out… Read more »

Biotech IPO scene shifts into pre-holiday slow gear, but several former IPOs are soaring with analysts saying Buy, Buy, Buy!

IPO Sector: US tech IPOs have mostly vanished in the fourth quarter following disappointments from multiple fast-growing, unprofitable unicorns. Healthcare (55% of 4Q IPOs) and Chinese issuers (24%) have hogged… Read more »

Healthcare stocks forge ahead despite trade-wars jitters; but that makes sense if you think about it.

Currently considered a “hedge” against the US-China trade clashes, which don’t bear directly on the provision of healthcare here in the US, here are the three top winners and a… Read more »

Hillary not cool with Elizabeth Warren’s “Medicare for All;” neither are many docs.

The News: Hillary Clinton, the 2016 Democratic nominee, said last Wednesday she hoped for a return to “boring, normal times” after the 2020 election, voicing skepticism of her party’s populist… Read more »